Tremelimumab
- Generic Name
- Tremelimumab
- Brand Names
- Imjudo, Tremelimumab AstraZeneca
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 745013-59-6
- Unique Ingredient Identifier
- QEN1X95CIX
- Background
Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces tu...
- Indication
Tremelimumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma in combination with durvalumab. It is also indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC)
- Associated Therapies
- -
Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors
- First Posted Date
- 2019-06-11
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Registration Number
- NCT03982173
A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)
- Conditions
- Interventions
- First Posted Date
- 2019-06-05
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 460
- Registration Number
- NCT03975114
- Locations
- 🇮🇹
Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, Italy
Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC
- Conditions
- Interventions
- First Posted Date
- 2019-05-29
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 96
- Registration Number
- NCT03965468
- Locations
- 🇨🇭
Kantonsspital Winterthur, Winterthur, Switzerland
🇮🇹European Institute of Oncology, Milano, Italy
🇮🇹Istituto Oncologico Veneto - Irccs, Padova, Italy
Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Federation Francophone de Cancerologie Digestive
- Target Recruit Count
- 107
- Registration Number
- NCT03959293
- Locations
- 🇫🇷
Ch - Hôpital Claude Bernard, Albi, France
🇫🇷Chu - Hôpital Sud, Amiens, France
🇫🇷Privé - Clinique de L'Europe, Amiens, France
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-05-06
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 22
- Registration Number
- NCT03937830
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-04-22
- Last Posted Date
- 2024-11-28
- Target Recruit Count
- 25
- Registration Number
- NCT03923270
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Improve Checkpoint-blockade Response in Advanced Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-03-12
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 53
- Registration Number
- NCT03871036
- Locations
- 🇳🇱
Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
- First Posted Date
- 2019-02-20
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 60
- Registration Number
- NCT03847649
- Locations
- 🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦Windsor Regional Cancer Centre, Windsor, Ontario, Canada
🇨🇦BCCA - Vancouver, Vancouver, British Columbia, Canada
Durvalumab Plus Tremelimumab for the Treatment of Patients with Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial
- Conditions
- Interventions
- First Posted Date
- 2018-11-27
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
- Target Recruit Count
- 79
- Registration Number
- NCT03753919
- Locations
- 🇪🇸
Hospital Clínic Barcelona, Barcelona, Spain
🇪🇸Hospital Universitario Virgen de la Victoria, Málaga, Spain
🇪🇸Clínica Universidad de Navarra, Pamplona, Spain
Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.
- Conditions
- Interventions
- First Posted Date
- 2018-10-12
- Last Posted Date
- 2024-01-05
- Target Recruit Count
- 106
- Registration Number
- NCT03704480
- Locations
- 🇫🇷
Hôpital Saint Eloi, Montpellier, France
🇫🇷CHU Henri Mondor, Créteil, France
🇫🇷CHU Dijon, Dijon, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.